Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

Prostate-specific antigen (PSA) testing may not accurately pinpoint levels at which transgender women on estrogen therapy may be at risk of developing prostate cancer, according to data from the ...

Screening PSA levels at aged 65-69 may inform the decision to continue or discontinue prostate cancer screening after age 70 years, regardless of patient race and ethnicity. The absolute risks of ...